Highlights include:
• Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.
• MGUS risk in relatives of patients with multiple myeloma.
• Costs of peripheral neuropathy in patients treated for multiple myeloma.
Download here: Multiple Myeloma Research Review Issue 30